The Interleukin-1 axis and cutaneous inflammation

165Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Since the discovery that epidermal cell-derived thymocyte-activating factor was identical to interleukin (IL)-1α and -β in 1986, these molecules have been implicated in the pathogenesis of skin diseases. In 1995, it has become clear that a group of gene products function to regulate the activity of IL-1. IL-1α and mature 17-kD IL-1β (cleaved from precursor by IL-1β-converting enzyme) bind to the type 1 IL-1 receptor to transduce a signal. This process can be antagonized at the level of the receptor by two distinct forms of the IL-1 receptor antagonist, which bind to the type I receptor but do not transduce a signal. The process can also be antagonized at the level of the ligand by either cell-bound or soluble type 2 IL-1 receptor. This type 2 IL-1 receptor binds ligand but does not transduce a signal Keratinocytes can make each of these variables in vitro, and the balance between agonists and antagonists dictates the biologic outcome of a putative IL-1-mediated event. - Transgenic mice that overexpress - each of these factors individually in epidermis will be useful for enhancing our understanding of the cutaneous biology of IL-1.

Cite

CITATION STYLE

APA

Kupper, T. S., & Groves, R. W. (1995). The Interleukin-1 axis and cutaneous inflammation. In Journal of Investigative Dermatology (Vol. 105, pp. S62–S66). Nature Publishing Group. https://doi.org/10.1038/jid.1995.13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free